The FDA has approved a label expansion for once-weekly tirzepatide for adults with overweight and obesity, allowing the medication to be used with a pen that is equipped with four doses of the drug, ...
Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include the four-dose single-patient use KwikPen® that ...
6d
Novo hoped its next obesity drug would close the gap. Instead, it may have widened Eli Lilly’s lead.
With U.S. arch rival Eli Lilly streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk needed ...
COPENHAGEN, Feb 23 (Reuters) - Novo Nordisk's next-generation obesity drug CagriSema underperformed Eli Lilly's Zepbound in ...
With U.S. arch rival Eli Lilly streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk needed was to give it a helping hand. Then came the latest trial data for ...
Lilly launches four-dose Zepbound KwikPen in the US. Self-pay starter price begins at $299 per month. Move aims to improve retention in crowded GLP-1 market. Millions of people on GLP-1 weight-loss ...
Moby THE GIST. Novo Nordisk just learned the hard way that in the obesity drug arms race, close is not good enough. A key ...
Novo Nordisk has said it will invest DKK 3.2 billion (€432 million) in a manufacturing plant in Ireland that will be used to ...
The Tennessee Poison Center is seeing a sharp increase in calls related to tirzepatide and semaglutide exposure — two ...
3d
California patients got sick after taking GLP-1s, other drugs made by Empower Pharmacy, records show
Empower Pharmacy could be banned from doing business in California after the state's pharmacy board moved to revoke Empower’s ...
The market for weight-loss drugs is booming - but the pioneer in the field is shedding profits and share value, writes Adam Maguire ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results